Cargando…

Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry

Detalles Bibliográficos
Autores principales:	Noori, Somayya, Wijnands, Charissa, Langerhorst, Pieter, Bonifay, Vincent, Stingl, Christoph, Touzeau, Cyrille, Corre, Jill, Perrot, Aurore, Moreau, Philippe, Caillon, Hélène, Luider, Theo M., Dejoie, Thomas, Jacobs, Joannes F. M., van Duijn, Martijn M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957984/ https://www.ncbi.nlm.nih.gov/pubmed/36828828 http://dx.doi.org/10.1038/s41408-023-00803-z

Ejemplares similares

B04 IMPLEMENTING M-PROTEIN DIAGNOSTICS IN MULTIPLE MYELOMA PATIENTS USING ULTRA-SENSITIVE TARGETED MASS SPECTROMETRY DATA AND AN OFF-THE-SHELF CALIBRATOR
por: Wijnands, C., et al.
Publicado: (2023)

P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT)
por: Bonifay, V., et al.
Publicado: (2023)

Retrospective Longitudinal Monitoring of Multiple Myeloma Patients by Mass Spectrometry Using Archived Serum Protein Electrophoresis Gels and De Novo Sequence Analysis
por: Noori, Somayya, et al.
Publicado: (2022)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients’ selection and perspective
por: Trudel, Sabrina, et al.
Publicado: (2019)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03)
por: van de Wyngaert, Zoe, et al.
Publicado: (2023)

P37 MULTIPLE MYELOMA MONITORING FROM ARCHIVED SERUM PROTEIN ELECTROPHORESIS GELS BY MASS SPECTROMETRY AND DE NOVO SEQUENCING
por: Noori, S., et al.
Publicado: (2023)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Interest of Pet Imaging in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2019)

FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients
por: Bailly, Clément, et al.
Publicado: (2017)

Difficulties in immunofixation analysis: a concordance study on the IFM 2007-02 trial
por: Caillon, H, et al.
Publicado: (2013)

When dystrophic plasma cells do not recognize themselves in the mirror
por: Rieu, Jean‐Baptiste, et al.
Publicado: (2020)

Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease
por: Lodé, L, et al.
Publicado: (2013)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

S186: ACQUIRED RESISTANCE TO BISPECIFIC ANTIBODIES BY GENETIC OR EPIGENETIC INACTIVATION OF THE TARGET IN MULTIPLE MYELOMA
por: Derrien, Jennifer, et al.
Publicado: (2023)

An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions
por: Dekker, Lennard J. M., et al.
Publicado: (2010)

Immune Repertoire after Immunization As Seen by Next-Generation Sequencing and Proteomics
por: VanDuijn, Martijn M., et al.
Publicado: (2017)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

Novel Antibody–Peptide Binding Assay Indicates Presence of Immunoglobulins against EGFR Phospho-Site S1166 in High-Grade Glioma
por: Zeneyedpour, Lona, et al.
Publicado: (2022)

Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature
por: Cailleteau, Axel, et al.
Publicado: (2021)

Gamma heavy chain disease associated with rheumatoid arthritis: a case report
por: Danic, Gwenvaël, et al.
Publicado: (2021)

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma
por: Benaniba, Lina, et al.
Publicado: (2019)

L’hyponatrémie semble être un facteur prédictif d’évolution défavorable dans l’infection COVID-19
por: Letellier, T., et al.
Publicado: (2020)

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
por: Seiller, Carolane, et al.
Publicado: (2020)

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials
por: Michaud-Robert, Anne-Victoire, et al.
Publicado: (2020)

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY
por: Tan, Carlyn, et al.
Publicado: (2023)

Glycoproteomics in Cerebrospinal Fluid Reveals Brain-Specific Glycosylation Changes
por: Baerenfaenger, Melissa, et al.
Publicado: (2023)

Peptides from the Variable Region of Specific Antibodies Are Shared among Lung Cancer Patients
por: de Costa, Dominique, et al.
Publicado: (2014)

Label-free peptide profiling of Orbitrap™ full mass spectra
por: Titulaer, Mark K, et al.
Publicado: (2011)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u2ik0ttubni756nnje0hoe22ln